Company performance
Add to research
Current Price
as of Feb 07, 2025$25.26
P/E Ratio
29.71
Market Cap
$47.43B
Description
Add to research
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
Metrics
Add to research
Overview
- HQTokyo, TY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- Ticker4568
- Price$25.257734+0.06%
Trading Information
- Market cap$47.43B
- Float85.46%
- Average Daily Volume (1m)5,362,360
- Average Daily Volume (3m)4,913,497
- EPS$129.03
Company
- Revenue$1.80T
- Rev growth (1yr)8.48%
- Net income$61.93B
- Gross margin73.52%
- EBITDA margin16.27%
- EBITDA$78.88B
- EV$7.64T
- EV/Revenue4.25
- P/E29.71
- P/S4.03
- P/B4.44
- Debt/Equity6.24
Documents
Add to research
Factset Street Account
Factset